Loading...

MERCK Kommanditgesellschaft auf Aktien

MKKGYPNK
HealthcareDrug Manufacturers - Specialty & Generic
$26.43
$-0.23(-0.86%)

MERCK Kommanditgesellschaft auf Aktien (MKKGY) Stock Overview

Explore MERCK Kommanditgesellschaft auf Aktien’s financial performance, market position, analyst ratings, and future outlook.

Revenue Growth
0.78%
0.78%
Profit Growth
$6.38
1.66%
EPS Growth
$6.38
1.69%
Operating Margin
17.90%
1.00%
ROE
9.68%
1.66%
Dividend Yield
0.00%
75.35%
Analyst Recommendations data is not available for MKKGYAnalyst Recommendations details for MKKGY are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and electronics sectors worldwide. It discovers, develops, manufactures, and markets pharmaceutical and biological prescription drugs to treat neurology and immunology, oncology, fertility, and cardiology metabolism and endocrinology. The company also supplies products, tools, and services for research laboratories, pharma and biotech production, and industrial and testing laboratories. In addition, it offers material for integrated circuits, liquid crystals, organic light-emitting diodes, photoresists, smart antenna, and liquid crystal glazing solutions, as well as effect pigments for use in automotive coatings, cosmetics, industrial, and plastic applications. It has strategic alliances with Pfizer Inc.; agreement with Novartis AG; and license agreements with Debiopharm International SA and MoonLake Immunotherapeutics AG. The company was founded in 1668 and is headquartered in Darmstadt, Germany. MERCK Kommanditgesellschaft auf Aktien is a subsidiary of E. Merck Kommanditgesellschaft.

CEO

Ms. Belen Garijo Lopez M.D.

Employees

59,020

Headquarters

Frankfurter Strasse 250, Darmstadt

Founded

2007

Frequently Asked Questions